In three mouse tumor models (melanoma, glioma, colon carcinoma) Chen at al. showed that intratumorally administration of an IL-21-armed recombinant vaccinia virus, rTTVΔTK-IL-21, led to selective enrichment of immune effector cells at tumor site, long-lasting tumor regression and improved survival. This evidence concerns the gene IL21 and glioma.